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Abstract
Objective: The objective of this review was to provide dosing recommendations for percentage change in weekly warfarin
dose and rates of thrombotic and bleeding events in patients requiring long-term warfarin therapy after bariatric surgery.
Data Sources: A comprehensive literature search of PubMed (through April 5, 2021), Cochrane Library, and Google
Scholar (through April 5, 2021) databases was completed using the keywords warfarin OR vitamin k antagonist AND
bariatric surgery. Study selection and data extraction: Retrospective studies and matched-cohort studies evaluating
preoperative and postoperative use of warfarin after bariatric surgery for obesity were considered. Weekly dose defined
as sum of daily doses of warfarin for 7 consecutive days was a required outcome to be considered in this review. Patients
were excluded from review if post-operative dosage change was not reported. Data synthesis: Six studies were included
with a total of 160 patients who met the criteria. A decrease in average warfarin dose was seen in all studies, with
the largest decrease occurring at 1 month postsurgery followed by an upward trend toward baseline about 90 days
postsurgery. While thrombotic events were observed in none of the patients, there was an increased risk of bleeding in
patients, particularly in those who underwent roux-en-y gastric bypass (RYGB) surgery. Relevance to patient care
and clinical practice: The study provides a specific warfarin dosing titration regimen, as well as embolic and bleed risk
in post-bariatric surgery population. Conclusions: Clinicians may consider lowering warfarin weekly dose by about 25%
immediately postsurgery, with doses approaching closer to baseline about 90 days postsurgery.
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Introduction
The prevalence of obesity in the United States in 2018 was
about 42.4%. The annual health care costs for obese patients
in 2008 were estimated to be US$147 billion.1 Patients who
have morbid obesity are at higher risk of type 2 diabetes,
heart disease, cancer, and thromboembolic events.1,2
Bariatric surgery has been shown to reduce mortality rate,
lower blood pressure, reverse metabolic syndrome, and
increase the quality of life.3,4 As the most effective method
of weight loss in patients with moderate (body mass index
[BMI] ≥35 kg/m2) and severe (BMI ≥40 kg/m2) obesity,
there is an increase in the number of individuals undergoing
bariatric surgery.5 The different types of bariatric procedures available include roux-en-y gastric bypass (RYGB),
sleeve gastrectomy (SG), and adjustable gastric banding
(AGB). These procedures achieve weight loss by reducing
the stomach volume and limiting caloric intake by promoting early satiety or reducing the number of calories absorbed

by bypassing pancreatic secretions, bile acids, or the proximal jejunum and duodenum.6 While there are remarkable
positive outcomes of bariatric surgery, there are some medical and surgical complications postoperatively. These
include nutritional deficiencies, postsurgical thromboembolic risk, as well as bleeding risk.7
It is important to note that a sedentary lifestyle, immobility, and venous obstruction from obesity are risk factors for
the development of venous thromboembolism (VTE).8 In
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addition, patients undergoing bariatric surgery may have
various indications for anticoagulation use, such as atrial
fibrillation, prevention of VTE, genetic predisposition to
coagulation, or presence of mechanical heart valves.9
Clinicians must balance the risk of thromboembolism versus the risk of hemorrhaging from surgery. Warfarin is the
most widely used anticoagulant in the world and is the recommended anticoagulant after bariatric surgery.6,10
Warfarin is a weak acid that is unionized at normal stomach pH. The drug is extensively absorbed through the stomach and proximal small intestine and boasts a high
bioavailability. However, the absorption of warfarin is
dependent on exposure of the drug to the gastrointestinal
tract. RYGB and SG decrease the surface area in the stomach leading to a reduction in the absorption of warfarin.11,12
Dose adjustments of warfarin are further complicated by
the influence of dietary vitamin K. Warfarin’s mechanism
of action focuses on the antagonism of vitamin K-dependent
clotting factors. Vitamin K deficiency after bariatric surgery
leads to decreased vitamin k-dependent clotting factors and
affects warfarin dosage requirements.11 Finally, patients
who have undergone bariatric surgery require significant
lifestyle changes. Patients are encouraged to alter their diet
and exercise to aid in their weight loss. Overall, weight loss
can lead to an increase in international normalized ratio
(INR) and can therefore cause the need for warfarin dose
adjustments throughout the weight loss process.13,14 While
bariatric surgery alters drug absorption, weight, and diet—
all factors that may affect therapeutic anticoagulation
requirements—there is currently no formal guidance for
dose adjustment in this patient population. Although there is
a significant decrease in drug absorption after bariatric surgery, several studies have reported that warfarin may still be
absorbed in varying amounts due to its high bioavailability.15
This systematic review aims to compile case reports and
identify percent change in weekly warfarin dose and rates of
thrombotic and bleeding events in patients requiring longterm warfarin therapy after bariatric surgery.

Methods
Two reviewers examined, collected, and extracted data
from all relevant studies. This systematic review included a
search of PubMed, the Cochrane Library, and Google
Scholar databases with the following keywords: “warfarin”
OR “vitamin K antagonist” and “bariatric surgery.” From
this search, 23 articles were identified. Of these articles, 6
studies with 160 subjects that met review criteria were
included in the review. Retrospective studies evaluating
preoperative and postoperative use of warfarin after bariatric surgery for obesity were considered. Trials did not need
an active comparator to be included in this review. Weekly
dose must be an outcome measure to be considered in this
review but was not restricted to being the primary outcome
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measure. Weekly dose must be defined as the sum of daily
doses of warfarin for 7 consecutive days. No limitations
were applied for the year of publication. Participants of any
age, treatment duration, indication, dosage, and type of bariatric surgery were included. Patients were excluded from
review if postoperative dosage change was not reported.
One article was excluded because the bariatric surgery was
for an invasive adenocarcinoma of her gastric remnant. We
extracted several components of the case reports, including
age, sex, anticoagulation indication, percentage of dose
change, and events of bleeding and thrombosis to determine
whether there is need for warfarin dose adjustment following bariatric surgery.

Results
Of the 160 subjects, 44% were male. Atrial fibrillation was the
most common indication for anticoagulation followed by prior
deep vein thrombosis (DVT)/pulmonary embolism (PE), artificial valve, and genetic predisposition. Mean weekly warfarin
dose was between 37.08 and 58.4 mg. All patients were
severely obese, having a BMI > 40 kg/m2 (Table 1).7,16–20
A similar pattern of warfarin dose adjustment was
observed across all studies. Weekly warfarin dose decreased
immediately after surgery but returned close to baseline after
90 days (Figure 1). Interestingly, in the Steffen et al. study,
weekly dose increased after 90 days. The investigators note
that this comparison was not statistically significant due to
small sample size. Increased risk of bleeding is a common
complication after bariatric surgery. One study reports gastrointestinal bleeding (GIB) after bariatric surgery can occur
between 1.1% and 4% of patients. This increased incidence
can be due to bleeding at one of the staple lines or the overuse of anticoagulants.21 Bleeding was reported in 17 patients.
Of the 13 patients who experienced bleeding in the Bechtel
et al. study, 11 occurred within 30 days of bariatric surgery.
Six developed gastrointestinal tract hemorrhage and all
underwent RYGB. Similarly in the Schullo et al. study, the 2
patients who experienced bleeding underwent RYGB and
had GIB. One patient presented with bright red blood in her
stool on postoperative day 8, had an INR of 2.9, and was
using enoxaparin postoperatively. The second patient presented on day 21 with black stool and had an INR of 9.8. The
reported incidence of DVT post bariatric surgery is between
0.12% and 3.8% Thrombotic events were observed in 0
patients (Table 2).

Discussion
This is the largest compilation of case series summarizing
several different published studies and providing clinical
guidance to clinicians managing anticoagulation regimens
for patients after bariatric surgery. In each of the studies
mentioned above, the required warfarin dosage in order to
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Table 1. Baseline Characteristics of Study Patients.

Source

No. of Percent of
patients males (%)

Mean age
(years)

Bechtel et al.7

38

55.3

Bolduc et al.16

20

65

Irwin et al.17

27

18.5

Schullo-Feulner
et al.18

10

50

57

Steffen et al.19

12

33.33

52

Strong et al.20

53

43.4

Age: 30-39
(4/38), 40-49
(11/38), 50-59
(7/38), 60+
(16/38)
54

56.9

RYGB: 54.8
SG: 53.7

Mean baseline
weekly warfarin Type of gastric
Baseline
Indications for anticoagulation
dose (mg)
bypass surgery BMI (kg/m2)
Arrhythmia: 19/38
DVT/PE: 12/38
Genetic predisposition: 5/38
Artificial valve: 2/38

NR

AF: 14/20
43.8
Mechanical heart valve: 3/20
DVT/PE: 2/20
Unknown: 1/20
AF: 3/27
47.9
Mechanical heart valve 9/27
History of DVT 11/27
History of PE 4/27
AF: 6/10
50.65
DVT/PE 2/10
DVT 1/10
Recurrent DVT 1/10
DVT prophylaxis (6/12)
37.08
AF (6/12)
Prior VTE: 18 (34.0%)
RYGB: 58.4
AF: 23 (43.4%)
SG: 48.2
Mechanical heart valve: 3 (5.7%)
Recurrent VTE: 58.5%

NR

NR

Standard
BPD/DS: 14
Modified BPD/
DS: 6
GB: 5
RYGB: 22

53

GB: 3
RYGB: 7

NR

RYGB: 12

48.1

RYGB: 31
SG: 22

RYGB: 49.4
SG: 53.3

50.2

Abbreviations: BPD/DS, biliopancreatic diversion with duodenal switch; BMI, body mass index; DVT, deep vein thrombosis; GB, gastric banding; NR,
not reported; PE, pulmonary embolism; RYGB, roux-en-y gastric bypass; SG, sleeve gastrectomy.

Table 2. Embolic and Bleed Risk Post-Bariatric Surgery.
Source
Bechtel et al.7
Bolduc et al.16
Irwin et al.17
Schullo-Feulner et al.18
Steffen et al.19
Strong et al.20

Figure 1. Percent decrease of warfarin dosing requirements
after bariatric surgery.

remain in therapeutic range decreased after bariatric surgery with patients requiring lower doses than baseline prior
to bariatric surgery. While the dosing did reduce significantly at first, the dose adjustments thereafter should require
closer monitoring to allow for safer dose adjustments based
on the INR. This review identified warfarin weekly dose to
reach closer to prior baseline weekly dose about 90 days
after surgery. Furthermore, information is available on the

Bleeding (no.)

Thrombosis (no.)

13
NR
2
2
0
N/A

NR
NR
0
0
0
N/A

INR readings of two patients who experienced bleeding
after bariatric surgery while on warfarin, one of which was
supratherapeutic. However, there are no data available for
the other bleed events and hence unable to determine cause
for bleeding.
This review identified that all postoperative bleeding
episodes were reported in the patients who underwent
RYGB surgery. However, these data are inconclusive since
they are represented by a very small patient population.
Further studies are needed to determine differences in bleed
risk depending on the type of bariatric surgery. Three of the
identified studies did not report embolic risk data, and the
others reported no thrombotic events. Note, bariatric surgery had a high risk of VTE, especially for older patients. A
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large population-based cohort study has reported bariatric
surgery to have a high risk of VTEs, particularly in the older
patient population.22 Hence, further studies evaluating
embolic risk of patients should be studied to further guide
anticoagulation management strategies.
Our study did have some limitations. The retrospective
nature of the studies resulted in incomplete collection of
baseline characteristics, such as comorbidities, BMI, and
concomitant medications. This is a drawback because many
medications interact with warfarin, warranting a dosage
change. In addition, some studies did not report bleeding or
thromboembolism as noted above. The exclusion criteria
and follow-up duration were not consistent in all studies,
but follow-up did last at least 3 months in each case.

Relevance to Patient Care and Clinical Practice
The study provides a specific warfarin dosing titration regimen, as well as embolic and bleed risk in post-bariatric surgery population.

Conclusion
Our systematic review identified dose requirement decreased
postoperatively. Clinicians may consider lowering warfarin
weekly dose by about 25% immediately post surgery. This
initial decrease was followed by an increase toward baseline
dose seen about 90 days after the procedure. However,
patients rarely need their prior baseline warfarin dose to
remain therapeutic. Finally, due to increased bleed risk and
unknown warfarin absorption in the studied population,
patients on warfarin after bariatric surgery should be closely
monitored to ensure the safety and efficacy of their anticoagulation therapy.
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